Literature DB >> 22991405

PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design.

Margaret M Redfield1, Barry A Borlaug, Greg D Lewis, Selma F Mohammed, Marc J Semigran, Martin M Lewinter, Anita Deswal, Adrian F Hernandez, Kerry L Lee, Eugene Braunwald.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22991405      PMCID： PMC3530955          DOI： 10.1161/CIRCHEARTFAILURE.112.969071

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN： 1941-3289            Impact factor:   8.790


× No keyword cloud information.
  71 in total

1.  Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure.

Authors:  Dalane W Kitzman; William C Little; Peter H Brubaker; Roger T Anderson; W Gregory Hundley; Christian T Marburger; Bridget Brosnihan; Timothy M Morgan; Kathryn P Stewart
Journal:  JAMA       Date:  2002-11-06       Impact factor: 56.272

2.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.

Authors:  Eiki Takimoto; Hunter C Champion; Manxiang Li; Diego Belardi; Shuxun Ren; E Rene Rodriguez; Djahida Bedja; Kathleen L Gabrielson; Yibin Wang; David A Kass
Journal:  Nat Med       Date:  2005-01-23       Impact factor: 53.440

3.  Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism.

Authors:  D W Kitzman; M B Higginbotham; F R Cobb; K H Sheikh; M J Sullivan
Journal:  J Am Coll Cardiol       Date:  1991-04       Impact factor: 24.094

4.  Predicted values for clinical exercise testing.

Authors:  J E Hansen; D Y Sue; K Wasserman
Journal:  Am Rev Respir Dis       Date:  1984-02

5.  Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy.

Authors:  Markus P Schlaich; David M Kaye; Elisabeth Lambert; Marcus Sommerville; Flora Socratous; Murray D Esler
Journal:  Circulation       Date:  2003-07-07       Impact factor: 29.690

6.  Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations.

Authors:  Miho Kawaguchi; Ilan Hay; Barry Fetics; David A Kass
Journal:  Circulation       Date:  2003-02-11       Impact factor: 29.690

7.  Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias.

Authors:  Steven L Higgins; John D Hummel; Imran K Niazi; Michael C Giudici; Seth J Worley; Leslie A Saxon; John P Boehmer; Michael B Higginbotham; Teresa De Marco; Elyse Foster; Patrick G Yong
Journal:  J Am Coll Cardiol       Date:  2003-10-15       Impact factor: 24.094

8.  Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial.

Authors:  James B Young; William T Abraham; Andrew L Smith; Angel R Leon; Randy Lieberman; Bruce Wilkoff; Robert C Canby; John S Schroeder; L Bing Liem; Shelley Hall; Kevin Wheelan
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

9.  Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart.

Authors:  Fadi Salloum; Chang Yin; Lei Xi; Rakesh C Kukreja
Journal:  Circ Res       Date:  2003-03-13       Impact factor: 17.367

10.  Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.

Authors:  S Ziesche; F R Cobb; J N Cohn; G Johnson; F Tristani
Journal:  Circulation       Date:  1993-06       Impact factor: 29.690
View more
  62 in total

1.  Exercise-induced pulmonary artery hypertension in a patient with compensated cardiac disease: hemodynamic and functional response to sildenafil therapy.

Authors:  Lazaros Nikolaidis; Nabeel Memon; Brian O'Murchu
Journal:  Tex Heart Inst J       Date:  2015-02-01

2.  Experimentally Increasing the Compliance of Titin Through RNA Binding Motif-20 (RBM20) Inhibition Improves Diastolic Function In a Mouse Model of Heart Failure With Preserved Ejection Fraction.

Authors:  Mei Methawasin; Joshua G Strom; Rebecca E Slater; Vanessa Fernandez; Chandra Saripalli; Henk Granzier
Journal:  Circulation       Date:  2016-09-14       Impact factor: 29.690

3.  Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial.

Authors:  Adam D DeVore; Steven McNulty; Fawaz Alenezi; Mads Ersboll; Justin M Vader; Jae K Oh; Grace Lin; Margaret M Redfield; Gregory Lewis; Marc J Semigran; Kevin J Anstrom; Adrian F Hernandez; Eric J Velazquez
Journal:  Eur J Heart Fail       Date:  2017-02-14       Impact factor: 15.534

Review 4.  Titin is a major human disease gene.

Authors:  Martin M LeWinter; Henk L Granzier
Journal:  Circulation       Date:  2013-02-26       Impact factor: 29.690

5.  High prevalence of subclinical cerebral infarction in patients with heart failure with preserved ejection fraction.

Authors:  Rebecca J Cogswell; Faye L Norby; Rebecca F Gottesman; Lin Y Chen; Scott Solomon; Amil Shah; Alvaro Alonso
Journal:  Eur J Heart Fail       Date:  2017-07-24       Impact factor: 15.534

6.  Pulmonary hypertension associated with heart failure with preserved ejection fraction: acute hemodynamic effects of inhaled iloprost.

Authors:  Nicole L Grossman; Christopher A Fiack; Janice M Weinberg; Denis V Rybin; Harrison W Farber
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

Review 7.  Therapeutic potential of PDE modulation in treating heart disease.

Authors:  Walter Knight; Chen Yan
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

8.  Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction.

Authors:  Muaz M Abudiab; Margaret M Redfield; Vojtech Melenovsky; Thomas P Olson; David A Kass; Bruce D Johnson; Barry A Borlaug
Journal:  Eur J Heart Fail       Date:  2013-02-20       Impact factor: 15.534

Review 9.  Pre-clinical diastolic dysfunction.

Authors:  Siu-Hin Wan; Mark W Vogel; Horng H Chen
Journal:  J Am Coll Cardiol       Date:  2013-11-27       Impact factor: 24.094

10.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.